Over the past decade, the number of clinical trials using a biosimilar treatment has been on the rise. GlobalData extracted all biosimilar drug trials up to December 21, 2018 and then broke them down by therapy area.
The largest number of biosimilar clinical trials took place in oncology, followed by immunology, hematological disorders, metabolic disorders, and musculoskeletal.
Go deeper with GlobalData
When split into phases GlobalData found biosimilar trials were most numerous in Phase I and Phase III across the major therapy areas (Figure 1). Musculoskeletal had the largest number of Phase I trials and a much higher number of Phase IV trials than any other therapy area. One of the largest treatment areas for approved biologic drugs is arthritis, so this may explain why there are so many post-marketing trials in this therapy area.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
